Illustration: Rebecca Zisser/Axios 

Americans on average are dying sooner, largely due to the country’s opioid epidemic. But a number of medical advances are helping people who have chronic diseases live longer.

What’s working: Medical researchers and venture capitalists told Axios that these drugs and treatments have immensely helped patients, or could change the face of medicine shortly.

  • Hepatitis C drugs sold by Gilead Sciences and AbbVie essentially eradicate the virus in as few as two months, although side effects vary.
  • Immunotherapy treatments, such as CAR-T, give patients the chance to fight off cancer with modified versions of their own immune cells.
  • New gene therapies are attacking rare disorders, such as one treatment that reverses a rare form of blindness.
  • Gene-modifying systems like CRISPR are giving scientists hope of treating disease at the DNA level.
  • Newer diabetes treatments have been shown to slow the costly and crippling long-term disease.

Be smart: The price tags are huge, and we still don’t know about all of their long-term side effects. There are always tradeoffs in health policy, but a breakthrough drug or treatment may not be all that valuable if people can’t access or afford it.

Go deeper:

Experts divided on trend toward smaller, targeted clinical trials

Go deeper

Felix Salmon, author of Capital
16 mins ago - Economy & Business

A white-collar crime crackdown

Illustration: Eniola Odetunde/Axios

America has waited a decade for an aggressive government crackdown on white-collar crime. Now, just before the election, and in the middle of a bull market, it has arrived.

Why it matters: When times are good, investors become more trusting and more greedy. That makes them more likely to put their money into fraudulent or criminal enterprises.

  • After a decade-long bull market, there is no shortage of those frauds to prosecute.
44 mins ago - Technology

Lawyers crystal-ball the Google antitrust case

Illustration: Eniola Odetunde/Axios

The Justice Department's antitrust suit against Google is a strong, straightforward monopoly case, competition lawyers and experts tell Axios. But that doesn't mean it'll be an easy journey for the government.

The big picture: Winning any antitrust case is a heavy lift. It's even more of a challenge to pull off victory in a future-looking case that seeks to make room for potential new competition to flourish.

The pandemic is getting worse again

Expand chart
Data: The COVID Tracking Project, state health departments; Note: Due to a database error, Missouri had a 3 day gap in reporting from Oct. 11-13; Map: Andrew Witherspoon/Axios

Every available piece of data proves it: The coronavirus pandemic is getting worse again, all across America.

The big picture: As the death toll ticks past 212,000, at a moment when containing the virus ought to be easier and more urgent than ever, we are instead giving it a bigger foothold to grow from.